JP4987001B2 - 癌および自己免疫障害を処置するためのｉｌ２８およびｉｌ２９の短縮型システイン変異体の使用法 - Google Patents

癌および自己免疫障害を処置するためのｉｌ２８およびｉｌ２９の短縮型システイン変異体の使用法 Download PDF

Info

Publication number
JP4987001B2
JP4987001B2 JP2008522947A JP2008522947A JP4987001B2 JP 4987001 B2 JP4987001 B2 JP 4987001B2 JP 2008522947 A JP2008522947 A JP 2008522947A JP 2008522947 A JP2008522947 A JP 2008522947A JP 4987001 B2 JP4987001 B2 JP 4987001B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
encoded
nucleotides
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008522947A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009502800A (ja
JP2009502800A5 (enExample
Inventor
ポール オー． シェパード
Original Assignee
ザイモジェネティクス リミテッド ライアビリティ カンパニー
ブリストル−マイヤーズ スクウィブ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザイモジェネティクス リミテッド ライアビリティ カンパニー, ブリストル−マイヤーズ スクウィブ カンパニー filed Critical ザイモジェネティクス リミテッド ライアビリティ カンパニー
Publication of JP2009502800A publication Critical patent/JP2009502800A/ja
Publication of JP2009502800A5 publication Critical patent/JP2009502800A5/ja
Application granted granted Critical
Publication of JP4987001B2 publication Critical patent/JP4987001B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2008522947A 2005-07-20 2006-07-20 癌および自己免疫障害を処置するためのｉｌ２８およびｉｌ２９の短縮型システイン変異体の使用法 Active JP4987001B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70095105P 2005-07-20 2005-07-20
US60/700,951 2005-07-20
US77126006P 2006-02-08 2006-02-08
US60/771,260 2006-02-08
PCT/US2006/028106 WO2007013944A2 (en) 2005-07-20 2006-07-20 Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders

Publications (3)

Publication Number Publication Date
JP2009502800A JP2009502800A (ja) 2009-01-29
JP2009502800A5 JP2009502800A5 (enExample) 2009-09-03
JP4987001B2 true JP4987001B2 (ja) 2012-07-25

Family

ID=37683787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008522947A Active JP4987001B2 (ja) 2005-07-20 2006-07-20 癌および自己免疫障害を処置するためのｉｌ２８およびｉｌ２９の短縮型システイン変異体の使用法

Country Status (7)

Country Link
US (5) US20070020227A1 (enExample)
EP (1) EP1909821A2 (enExample)
JP (1) JP4987001B2 (enExample)
AU (1) AU2006272937A1 (enExample)
CA (1) CA2616004A1 (enExample)
IL (1) IL188357A0 (enExample)
WO (1) WO2007013944A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271786A1 (en) * 2000-06-30 2002-01-14 Zymogenetics Inc. Interferon-like protein zcyto21
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
EP2251353B1 (en) * 2003-08-07 2013-03-06 ZymoGenetics, Inc. Homogeneous preparations of IL-29
EP1912668A2 (en) * 2005-07-20 2008-04-23 ZymoGenetics, Inc. Il28 and il29 truncated cysteine mutants and antiviral methods of using same
AU2006272937A1 (en) * 2005-07-20 2007-02-01 Bristol-Myers Squibb Company Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders
EP1931704B1 (en) 2005-10-04 2010-12-15 ZymoGenetics, L.L.C. Production and purification of il-29
JP2009115776A (ja) * 2007-07-11 2009-05-28 Ngk Spark Plug Co Ltd アンモニアガスセンサ
JP5083898B2 (ja) * 2007-07-11 2012-11-28 日本特殊陶業株式会社 アンモニアガスセンサ
RU2496514C2 (ru) * 2008-06-05 2013-10-27 Займоджинетикс, Инк. Применение пэгилированных интерферонов типа iii для лечения гепатита с
US20100316608A1 (en) * 2009-06-15 2010-12-16 Vijayaprakash Suppiah Method of Determining A Response To Treatment With Immunomodulatory Composition
FR2975185A1 (fr) * 2011-05-12 2012-11-16 Univ Claude Bernard Lyon Procede de determination in vitro de la presence d'une sclerose en plaques
CN104045704B (zh) * 2013-03-11 2016-08-10 中国医学科学院基础医学研究所 PEG化重组人IFN-λ1、其制备方法和用途
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CN103923209B (zh) * 2014-05-13 2016-06-22 北京凯因科技股份有限公司 一种Lambda干扰素突变体及聚乙二醇衍生物
CN105085658B (zh) * 2014-05-14 2019-12-24 杭州先为达生物科技有限公司 一种白细胞介素29突变体及聚乙二醇衍生物
DE102015001902A1 (de) * 2015-02-18 2016-08-18 Continental Reifen Deutschland Gmbh Verfahren zur Verbesserung der Haftung zwischen einem Verstärkungselement und einem elastomeren Matrixmaterial
CN107530338B (zh) 2015-04-21 2020-12-01 艾格尔峰生物制药有限公司 包含洛那法尼和利托那韦的药物组合物
KR20180110127A (ko) 2016-02-19 2018-10-08 아이거 바이오파마슈티컬스 인코포레이티드 인터페론 람다를 이용한 델타 간염 바이러스 감염의 치료
JP2019531729A (ja) * 2016-09-30 2019-11-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 変異体ｉｉｉ型インターフェロン及びシンセカイン
US20220378878A1 (en) * 2019-12-20 2022-12-01 The Council Of The Queensland Institute Of Medical Research Treatment of gastrointestinal disease
KR102226826B1 (ko) * 2020-08-06 2021-03-11 주식회사 휴벳바이오 버피 코트 시료에 사용하기 위한 췌장암 진단용 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI86558C (fi) 1980-01-08 1992-09-10 Biogen Inc Dna- sekvenser, rekombinant-dna- molekyler och foerfaranden foer framstaellning av humant interferon av -typ och val av dna-sekvensen.
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6468776B1 (en) * 2000-03-03 2002-10-22 Zymogenetics, Inc. Human serine protease
AU2001271589A1 (en) * 2000-06-30 2002-01-14 Zymogenetics Inc. Mammalian secreted proteins
AU2001271786A1 (en) * 2000-06-30 2002-01-14 Zymogenetics Inc. Interferon-like protein zcyto21
EP2298789B1 (en) 2000-09-08 2012-03-14 Schering Corporation Mammalian genes; related reagents and methods
US7038032B2 (en) * 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
CN100482684C (zh) * 2001-04-20 2009-04-29 津莫吉尼蒂克斯公司 细胞因子蛋白质家族
PL373008A1 (en) * 2001-05-10 2005-08-08 Immunex Corporation Cytokine polypeptides
WO2003066002A2 (en) * 2002-02-08 2003-08-14 University Of Medicine And Dentistry Of New Jersey IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION
BR0309401A (pt) * 2002-04-19 2007-02-21 Zymogenetics Inc polinucleotìdeo isolado, vetor de expressão, célula cultivada, método para produzir polipeptìdeos, e um anticorpo para um polipeptìdeo, e, anticorpo
EP1575609A4 (en) 2002-10-23 2010-12-15 Zymogenetics L L C METHOD FOR THE TREATMENT OF VIRUS INFECTIONS USING IL-28 AND IL-29
EP2251353B1 (en) * 2003-08-07 2013-03-06 ZymoGenetics, Inc. Homogeneous preparations of IL-29
CA2558829C (en) 2004-04-02 2014-03-11 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29 cysteine mutants
AU2005266892B2 (en) * 2004-07-29 2011-03-03 Bristol-Myers Squibb Company Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
CN1305902C (zh) 2004-11-25 2007-03-21 汕头大学医学院 一种人白细胞介素29的生产方法及重组il－29工程菌
AU2006272937A1 (en) * 2005-07-20 2007-02-01 Bristol-Myers Squibb Company Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders
EP1912668A2 (en) * 2005-07-20 2008-04-23 ZymoGenetics, Inc. Il28 and il29 truncated cysteine mutants and antiviral methods of using same
EP1931704B1 (en) * 2005-10-04 2010-12-15 ZymoGenetics, L.L.C. Production and purification of il-29

Also Published As

Publication number Publication date
CA2616004A1 (en) 2007-02-01
WO2007013944A3 (en) 2007-05-18
AU2006272937A1 (en) 2007-02-01
WO2007013944A2 (en) 2007-02-01
US20100298230A1 (en) 2010-11-25
US20120251488A1 (en) 2012-10-04
IL188357A0 (en) 2008-04-13
US8313739B2 (en) 2012-11-20
US20140044676A1 (en) 2014-02-13
US20070020227A1 (en) 2007-01-25
EP1909821A2 (en) 2008-04-16
JP2009502800A (ja) 2009-01-29
AU2006272937A8 (en) 2008-02-28
US20110177024A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
US8313739B2 (en) Use of truncated cysteine IL28 and IL29 Mutants to treat cancers and autoimmune disorders
US7786075B2 (en) Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
AU2008230054B2 (en) Novel cytokine zcytor17 ligand
US6929932B2 (en) IL-21 antagonists
JP4808157B2 (ja) Ｉｌ−２８およびｉｌ−２９の均一な調製物
CA2487133A1 (en) Use of il-21 in cancer and other therapeutic applications
JP2007528719A5 (enExample)
JP2009502803A (ja) Ｉｌ−２８およびｉｌ−２９のシステイン欠失変異体、ならびにそれを用いる抗ウイルス法
EP1501936A2 (en) Cytokine protein family
CN101031316A (zh) Il－28和il－29治疗癌症和自身免疫性疾病的用途
HK1162323A (en) Use of il-28 and il-29 to treat cancer
ES2353150T3 (es) Familia de proteínas de citoquinas.
RU2372356C2 (ru) Полипептид с антивирусной активностью, его получение и применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090714

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20091224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120308

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120409

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120424

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4987001

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150511

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250